Andrew Pajak, DO
Pulmonary Disease · Easton, MDNPI 1316406382
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $428 of the $528 with a category attached, or 81.1%. It is spread thinly across 14 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $355, 3.7 times the $96 reported in 2023. That places this record below the midpoint for pulmonary disease clinicians in MD, where the typical reported total is $830.
Across 21 payments — averaging $25.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$100
- AstraZeneca$73
- GSK$62
- Sanofi$60
- Insmed, Inc.$44
- Takeda Pharmaceuticals U.S.A., Inc.$40
- plus $150 from 8 others
What the payments were for
- Food & beverage$42881%
- Education$10019%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 1 | $100 |
| AstraZeneca(2 entities) | 3 | $73 |
| GSK | 3 | $62 |
| Sanofi | 3 | $60 |
| Insmed, Inc. | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $40 |
| Viatris Specialty LLC | 1 | $24 |
| Mylan Specialty L.p. | 1 | $22 |
| Pulmonx Corporation | 1 | $21 |
| Scpharmaceuticals Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Grifols USA, LLC | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
How this compares
$528 in reported general payments places this provider in the 45th percentile of 297 pulmonary disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Easton
- Alan SchwartzBaltimore$1.3M
- Hitesh BatraBaltimore$611K
- Lonny YarmusBaltimore$582K
- Robert WiseBaltimore$389K
- da Wei LiaoBethesda$310K
- Ko Pen WangBaltimore$280K
- Hans LeeBaltimore$277K
- Angela ArgentoBaltimore$269K
- Michael DrummondBaltimore$263K
- Jason AkulianBaltimore$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.